openPR Logo
Press release

Autoimmune Hepatitis Pipeline, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

05-02-2024 10:29 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Autoimmune Hepatitis Pipeline

Autoimmune Hepatitis Pipeline

DelveInsight's, "Autoimmune Hepatitis Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Autoimmune Hepatitis pipeline landscape. It covers the Autoimmune Hepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autoimmune Hepatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Autoimmune Hepatitis Pipeline Report
• DelveInsight's Autoimmune Hepatitis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Autoimmune Hepatitis treatment.
• The leading companies working in the Autoimmune Hepatitis Market include Novartis, TaiwanJ Pharmaceuticals Co., Ltd, Kezar Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Revive Therapeutics, Moderna, Inc., Parvus Therapeutics, Sigilon Therapeutics, Inc., Orbsen Therapeutics, and others.
• Promising Autoimmune Hepatitis Pipeline Therapies in the various stages of development include Zetomipzomib, HR19042 Capsules, JKB-122, budesonide, prednisone, VAY736, and others.
• February 2024:- Novartis Pharmaceuticals- This is a randomized, placebo-controlled, double-blind dose range study in autoimmune hepatitis. The study population consists of female and male adult autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care. The diagnosis of autoimmune hepatitis has to fulfill the IAIHG criteria and must be confirmed by liver histology.

Request a sample and discover the recent advances in Autoimmune Hepatitis Treatment Drugs @ Autoimmune Hepatitis Pipeline Report- https://www.delveinsight.com/sample-request/autoimmune-hepatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Autoimmune Hepatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autoimmune Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Autoimmune Hepatitis Overview
Autoimmune hepatitis refers to chronic and progressive inflammation of the liver from an unknown cause. The proposed mechanism for the development of autoimmune hepatitis is thought to be the interplay of genetic predisposition, an environmental trigger, and failure of the native immune system resulting in chronic inflammation of hepatocytes and subsequent fibrosis of the liver.

Find out more about Autoimmune Hepatitis Therapeutics Assessment @ Autoimmune Hepatitis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/autoimmune-hepatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Autoimmune Hepatitis Emerging Drugs Profile
• Ianalumab: Novartis
• JKB-122: TaiwanJ Pharmaceuticals

Autoimmune Hepatitis Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the Autoimmune Hepatitis therapies. The Autoimmune Hepatitis companies which have their Autoimmune Hepatitis drug candidates in the most advanced stage, i.e. phase II/III include, Novartis.

DelveInsight's Autoimmune Hepatitis pipeline report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Autoimmune Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Autoimmune Hepatitis Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Autoimmune Hepatitis Pipeline Therapies @ Autoimmune Hepatitis Clinical Trials Assessment

Scope of the Autoimmune Hepatitis Pipeline Report
• Coverage- Global
• Autoimmune Hepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Autoimmune Hepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Autoimmune Hepatitis Companies- Novartis, TaiwanJ Pharmaceuticals Co., Ltd, Kezar Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Revive Therapeutics, Moderna, Inc., Parvus Therapeutics, Sigilon Therapeutics, Inc., Orbsen Therapeutics, and others.
• Autoimmune Hepatitis Pipeline Therapies- Zetomipzomib, HR19042 Capsules, JKB-122, budesonide, prednisone, VAY736, and others.

Dive deep into rich insights for new drugs for Autoimmune Hepatitis Treatment, Visit @ Autoimmune Hepatitis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/autoimmune-hepatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Autoimmune Hepatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug name: Company name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II/III)
10. Ianalumab: Novartis
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. JKB-122: TaiwanJ Pharmaceuticals Co., Ltd
14. Drug profiles in the detailed report…..
15. Preclinical Stage Products
16. mRNA-6981: Moderna
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Autoimmune Hepatitis Key Companies
20. Autoimmune Hepatitis Key Products
21. Autoimmune Hepatitis- Unmet Needs
22. Autoimmune Hepatitis- Market Drivers and Barriers
23. Autoimmune Hepatitis- Future Perspectives and Conclusion
24. Autoimmune Hepatitis Analyst Views
25. Autoimmune Hepatitis Key Companies
26. Appendix

For further information on the Autoimmune Hepatitis Pipeline therapeutics, reach out to Autoimmune Hepatitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/autoimmune-hepatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Autoimmune Hepatitis Pipeline, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here

News-ID: 3482281 • Views:

More Releases from DelveInsight Business Research LLP

Gonorrhoea Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and Future Market Impact Revealed
Gonorrhoea Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Tri …
DelveInsight's "Gonorrhoea Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Gonorrhoea pipeline landscape. It covers the Gonorrhoea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gonorrhoea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Gonorrhoea pipeline products in this space. Explore our latest breakthroughs in Gonorrhoea Research. Learn
Glioblastoma Multiforme Market Size (7MM) was ~USD 835 million in 2023 and is expected to increase with a significant CAGR by 2034, estimates DelveInsight | Novocure, Roche (Genentech), Merck, Daiichi Sankyo, Novartis, Bayer, Aivita Biomedical and TAE Lif
Glioblastoma Multiforme Market Size (7MM) was ~USD 835 million in 2023 and is ex …
DelveInsight's "Glioblastoma Multiforme Market Insight, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Discover Key Insights into the Glioblastoma Multiforme Market with DelveInsight's In-Depth Report @ Glioblastoma Multiforme Market Size- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Glioblastoma Multiforme Market Report • In
Blepharitis Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight | Tarsus Pharmaceuticals Inc., LianBio LLC, Nicox Ophthalmics Inc., Eye Research Foundation Inc., Laboratoires Thea, Sun Pharmaceutical Industries Limited, Me
Blepharitis Treatment Market Size in the 7MM is expected to grow by 2034, estima …
DelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Blepharitis, historical and forecasted epidemiology, as well as the Blepharitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Explore the intricate details of the Blepharitis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Blepharitis Market Forecast @ https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, estimates DelveInsight | Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy bio, Imugene
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, estimates Delve …
DelveInsight's "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma, historical and forecasted epidemiology, as well as the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Explore the intricate details of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

All 5 Releases


More Releases for Autoimmune

Autoimmune Polyglandular Syndrome Market analysis reveals CAGR of 6.20 percent t …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Autoimmune Polyglandular Syndrome Type 1 Market - (By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Age of Onset (Childhood, Adult, Adolescent), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)),
Reshaping Autoimmune Therapy Landscape: Protheragen Announces Small Molecule Dru …
Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune diseases. New York, USA - Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune conditions. From target identification to preclinical studies, Protheragen leverages its expertise in small molecule drug design and development to offer tailored services that provide biotech and pharmaceutical companies
Autoimmune Disease Diagnosis Market - Strength in Knowledge, Defying Autoimmune …
Newark, New Castle, USA: The "Autoimmune Disease Diagnosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Autoimmune Disease Diagnosis Market: https://www.growthplusreports.com/report/autoimmune-disease-diagnosis-market/7616 This latest report researches the industry structure,
Autoimmune Drugs Market: Understanding How They Work and Their Importance in Tre …
Allied Market Research recently said Autoimmune diseases are a group of disorders in which the body's immune system attacks its own healthy tissues, mistaking them for foreign invaders. These diseases can affect any part of the body, including the joints, skin, and organs. They can be debilitating, chronic, and sometimes life-threatening. Autoimmune drugs are medications that help to suppress or modulate the immune system's response to prevent it from attacking
Autoimmune Disease Diagnostics Market: Growing Awareness among People about Auto …
According to the recent report by Transparency Market Research, the global autoimmune disease diagnostics market has a highly consolidated scenario. The market is dominated by a handful of players. However, these players have a stronghold over the dynamics of market and pose a great challenge for any new entrant to set its foot in the market. Read Report Overview - https://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html To reduce effects of such hindrances, the new entrants are
Autoimmune Disease Therapeutics Market Boost due to increase in incidence of aut …
According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is expected to reach $153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025. Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/5185?utm_source=openpr&utm_medium=Niranjan Autoimmune disease therapeutics include